<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65826">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02248922</url>
  </required_header>
  <id_info>
    <org_study_id>CTBM100CDE02</org_study_id>
    <secondary_id>2014-001204-21</secondary_id>
    <nct_id>NCT02248922</nct_id>
  </id_info>
  <brief_title>Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa</brief_title>
  <acronym>ELIXIR</acronym>
  <official_title>An 8 Week Open-label Interventional Multicenter Study to Evaluate the Lung Clearance Index as Endpoint for Clinical Trials in Cystic Fibrosis Patients ≥ 6 Years of Age, Chronically Infected With Pseudomonas Aeruginosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate lung clearance index (LCI) by a standardized
      procedure in a well characterized study setting and to assess feasibility of LCI as a more
      sensitive method than forced expiratory volume at 1 second (FEV1) to measure effectiveness
      of antibiotic therapy in patients with CF aged 6 years and older with mild to moderate lung
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 27, 2015</start_date>
  <completion_date type="Anticipated">May 12, 2017</completion_date>
  <primary_completion_date type="Anticipated">May 12, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lung Clearance Index</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>The Lung Clearance Index (LCI), measured by Multiple Breath Washout of a tracer gas reflects the obstruction of airways in the lung. A LCI of 7.5 and below is normal,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of FEV1</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>Change of FEV1 (Forced expiry volume in the first second) measured by Spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CFU</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>Microbacterial density of Pseudomonas aeruginosa in Sputum-Samples in CFU (Colony Forming Units) per gram sputum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of LCI</measure>
    <time_frame>Baseline, week 1</time_frame>
    <description>See Primary outcome measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of LCI, FEV1 and CFU</measure>
    <time_frame>week 4, week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Lung Infection With Pseudomonas Aeruginosa in Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Inhaled Tobramycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg nebulized Tobramycin twice a day (BID) 28days on / 28 days off or equivalent dry powder Tobramycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIS or TIP</intervention_name>
    <description>300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)</description>
    <arm_group_label>Inhaled Tobramycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF

          -  Patients with elevated LCI of ≥ 7.5 at screening

          -  Patients with FEV1 of ≥ 50% predicted at screening

          -  Use of inhaled Tobramycin in a 28 days on / off regimen in the past 3 months before
             screening

          -  chronic lung Infection with Pseudomonas aeruginosa

        Exclusion Criteria:

          -  Patients who are regularly receiving more than one class of inhaled anti-pseudomonal
             antibiotic

          -  Patients who have used oral or intravenous anti-pseudomonal antibiotics within 28
             days prior to on-phase of study drug

          -  Pregnant or nursing (lactating) women

          -  Change in dose, formulation or strength of the study drug in the past treatment cycle
             before screening

          -  History of hearing loss or chronic tinnitus

          -  Infection with Burkholderia cenocepacia complex

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jörg Ziegler, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharma GmbH, Nürnberg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 10, 2017</lastchanged_date>
  <firstreceived_date>September 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis, Pseudomonas aeruginosa, Lung Clearance Index, Multiple Breath Washout, Inhaled Tobramycin, Inhaled Antibiotics.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
